VXRT News and Press, Vaxart Inc. From 05/06/21

James River Group Holdings (JRVR) -23% after stock offering and Q1 earnings release.Fastly (FSLY) -19% on Q1 earnings release.Regional Health Properties (RHE) -15%.Rocket Companies (RKT) -13% on Q1 earnings release.Etsy (ETSY) -11% on Q1 earnings releas...

If you've ever ordered a piping hot pizza to your door, you already know that convenience is king. It's no secret that people are willing to pay for products that make their lives easier or less painful. But does that same principle hold up for products that consumers uniformly expect to be...

Things were looking gloomy for Vaxart (NASDAQ: VXRT) a few months ago. The clinical-stage biotech company reported that its COVID-19 vaccine candidate didn't produce neutralizing antibodies in a phase 1 trial. These antibodies are considered key since their role is to fight infectio...

Should Investors Be Watching These 4 Top Biotech Stocks Now? You can’t deny that 2020 was a banner year for biotech stocks . Sure, they are among the most volatile stocks in the stock market today , but investors have benefitted handsomely from some. Take Novavax ( ...

Shares of Vaxart (NASDAQ: VXRT) climbed on Tuesday after the biotech released promising data from a clinical trial of its oral coronavirus vaccine candidate. As of 3:30 p.m. EDT, Vaxart's stock price was up more than 12%. A phase 1 study showed Vaxart's vaccine to potentiall...

Vaxart (VXRT) shares are up more than 9.3% in late afternoon trading, a day after the stock dropped 26% due to disappointing Q1 earnings and a delay in a phase 2 trial of its oral COVID-19 vaccine candidate.However, shares rose more than 20% after-hours yesterday as the company repo...

Vaxart (NASDAQ: VXRT) , the biotech creating tablet-based vaccines, jumped 78.2% last month according to S&P Global Market Intelligence . The increase recovered some of the ground it lost after Phase 1 data from its COVID-19 vaccine disappointed investors in early February. ...

Vaxart ([[VXRT]] +16.3%) announces that it has enrolled the first subject in a Phase 1b boosting regimen trial of its norovirus vaccine candidate.The Phase 1b study is designed to enroll 30 subjects aged 18 to 55 years old, with endpoints being safety and immunogenicity.Subjects wil...

BioLineRx (BLRX) +62% on positive top-line results from GENESIS phase 3 trial.Cocrystal Pharma (COCP) +40%.Huttig Building Products, Inc. (HBP) +26% on Q1 results.Vaxart (VXRT) +20% as its oral COVID-19 vaccine shows potential to offer promising solution against variants.Precip...

Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year Study results may inform the COVID-19 oral vaccine program SOUTH SAN FRANCISCO, Calif., May 0...